Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01801917 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01801917 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT01801917, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).
Interventions
- DRUG Placebo
- DRUG BAF312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-04-24 |
| Est. Completion | 2016-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01801917
The ClinicalTrials.gov registry entry for NCT01801917 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01801917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01801917 about?
NCT01801917 is a clinical study titled "Efficacy and Tolerability of BAF312 in Patients With Polymyositis". This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).
What is the current status of trial NCT01801917?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2013-04-24. Estimated completion is 2016-08-05.
What interventions are being tested in trial NCT01801917?
The interventions under investigation include: Placebo (DRUG), BAF312 (DRUG).
Who is sponsoring clinical trial NCT01801917?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.